Outlook Therapeutics, Inc. (OTLK)
OTLK Stock Price Chart
Explore Outlook Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze OTLK price movements and trends.
OTLK Company Profile
Discover essential business fundamentals and corporate details for Outlook Therapeutics, Inc. (OTLK) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
14 Jun 2016
Employees
23.00
CEO
Robert Charles Jahr
Description
Outlook Therapeutics, Inc. is a biopharmaceutical company in the advanced stages of clinical development, focused on inventing and bringing to market monoclonal antibody treatments for various eye conditions. Its flagship drug candidate, ONS-5010, is an ophthalmic formulation of bevacizumab currently undergoing crucial Phase III clinical trials. This investigational product is being evaluated for its potential to treat wet age-related macular degeneration and other serious retinal diseases. The company has forged strategic collaboration and licensing agreements with several partners, including IPCA Laboratories Limited, Laboratorios Liomont, S.A. de C.V., BioLexis Pte. Ltd., and Zhejiang Huahai Pharmaceutical Co., Ltd. Incorporated in 2010, the firm was formerly known as Oncobiologics, Inc., changing its name to Outlook Therapeutics, Inc. in November 2018. Its corporate base is located in Iselin, New Jersey.
OTLK Financial Timeline
Browse a chronological timeline of Outlook Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 13 Aug 2026
EPS estimate is -$0.09, while revenue estimate is $4.83m.
Earnings released on 15 May 2026
EPS came in at -$0.16 falling short of the estimated -$0.12 by -33.33%, while revenue for the quarter reached $128.00k , missing expectations by -97.08%.
Earnings released on 17 Feb 2026
EPS came in at -$0.22 falling short of the estimated -$0.17 by -29.41%, while revenue for the quarter reached -$1.21m , missing expectations by -138.44%.
Earnings released on 19 Dec 2025
EPS came in at -$0.22 surpassing the estimated -$0.26 by +15.38%, while revenue for the quarter reached -$91.79k , missing expectations by -101.57%.
Earnings released on 14 Aug 2025
EPS came in at -$0.44 falling short of the estimated -$0.42 by -4.76%, while revenue for the quarter reached $1.51m , missing expectations by -74.25%.
Earnings released on 15 May 2025
EPS came in at -$0.40 surpassing the estimated -$0.55 by +27.27%.
Earnings released on 14 Feb 2025
EPS came in at -$0.89 falling short of the estimated -$0.85 by -4.71%.
Earnings released on 27 Dec 2024
EPS came in at -$0.77 surpassing the estimated -$0.83 by +7.23%.
Earnings released on 14 Aug 2024
EPS came in at -$0.83 surpassing the estimated -$1.06 by +21.70%.
Earnings released on 15 May 2024
EPS came in at -$1.55 falling short of the estimated -$0.88 by -76.14%.
Stock split effective on 14 Mar 2024
Shares were split 1 : 20 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 14 Feb 2024
EPS came in at -$0.80 surpassing the estimated -$1.00 by +20.00%.
Earnings released on 22 Dec 2023
EPS came in at -$1.00 matching the estimated -$1.00.
Earnings released on 14 Aug 2023
EPS came in at -$1.60 falling short of the estimated -$0.80 by -100.00%.
Earnings released on 15 May 2023
EPS came in at -$0.60 surpassing the estimated -$1.20 by +50.00%.
Earnings released on 14 Feb 2023
EPS came in at -$1.60 falling short of the estimated -$0.80 by -100.00%.
Earnings released on 29 Dec 2022
EPS came in at -$0.06 surpassing the estimated -$0.07 by +14.29%.
Earnings released on 10 Aug 2022
EPS came in at -$1.60 matching the estimated -$1.60.
Earnings released on 13 May 2022
EPS came in at -$1.80 falling short of the estimated -$1.40 by -28.57%.
Earnings released on 14 Feb 2022
EPS came in at -$1.60 falling short of the estimated -$1.40 by -14.29%.
Earnings released on 22 Dec 2021
EPS came in at -$1.60 falling short of the estimated -$1.40 by -14.29%.
Earnings released on 13 Aug 2021
EPS came in at -$1.40 surpassing the estimated -$1.60 by +12.50%.
OTLK Stock Performance
Access detailed OTLK performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
